TransMedics Group (NASDAQ:TMDX) Shares Gap Down – Time to Sell?

TransMedics Group, Inc. (NASDAQ:TMDX) gapped down prior to trading on Tuesday . The stock had previously closed at $85.14, but opened at $77.08. TransMedics Group shares last traded at $77.46, with a volume of 592,770 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on TMDX shares. JPMorgan Chase & Co. lowered their price target on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 29th. TD Cowen lowered their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a report on Monday, November 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Tuesday. Canaccord Genuity Group lowered their price objective on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research note on Wednesday, November 20th. Finally, Robert W. Baird cut their target price on TransMedics Group from $200.00 to $150.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $131.80.

TransMedics Group Trading Down 14.7 %

The company has a market cap of $2.44 billion, a PE ratio of 82.41 and a beta of 2.06. The company’s 50 day simple moving average is $110.21 and its two-hundred day simple moving average is $135.81. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The company had revenue of $108.76 million for the quarter, compared to analysts’ expectations of $115.00 million. During the same period in the previous year, the business posted ($0.12) EPS. The business’s revenue for the quarter was up 63.7% on a year-over-year basis. As a group, sell-side analysts anticipate that TransMedics Group, Inc. will post 1.01 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Tamer I. Khayal sold 2,958 shares of the firm’s stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the sale, the insider now owns 20,843 shares of the company’s stock, valued at $3,089,766.32. This trade represents a 12.43 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $153.42, for a total transaction of $1,323,247.50. Following the completion of the transaction, the chief executive officer now owns 61,643 shares of the company’s stock, valued at $9,457,269.06. This represents a 12.27 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 26,958 shares of company stock valued at $3,470,328. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently modified their holdings of the company. International Assets Investment Management LLC acquired a new stake in TransMedics Group in the second quarter valued at $47,000. USA Financial Formulas acquired a new stake in shares of TransMedics Group during the 3rd quarter worth about $55,000. Quarry LP lifted its stake in TransMedics Group by 557.1% during the third quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares during the last quarter. National Bank of Canada FI boosted its holdings in TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after purchasing an additional 262 shares in the last quarter. Finally, J.Safra Asset Management Corp increased its stake in TransMedics Group by 649.2% in the second quarter. J.Safra Asset Management Corp now owns 442 shares of the company’s stock valued at $67,000 after purchasing an additional 383 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.